I am a
Home I AM A Search Login

Papers of the Week

2021 Feb 03

Respir Res



Temporarily switching from oral to intravenous selexipag in patients with pulmonary arterial hypertension: safety, tolerability, and pharmacokinetic results from an open-label, phase III study.


Klose H, Chin KM, Ewert R, Gall H, Parambil J, Poch D, Seyfarth H-J, Axelsen LN, Hsu Schmitz S-F, Stein C, Preston IR
Respir Res. 2021 Feb 03; 22(1):34.
PMID: 33536021.


The oral IP receptor agonist selexipag is approved for the long-term treatment of pulmonary arterial hypertension (PAH). Treatment interruptions should be avoided due to the progressive nature of the disease. An intravenous (IV) formulation of selexipag was developed to provide a treatment option for short-term interruptions to oral selexipag. In this prospective, multicenter, open-label study, the safety, tolerability, and pharmacokinetics of temporarily switching between oral and IV selexipag were investigated (NCT03187678, ClinicalTrials.gov).